News blog

Epigenetic drug may lower cholesterol build-up

With a market worth more than US$20.1 billion, drug companies have long competed in a race to develop cholesterol medicines that work better than statins. Today, researchers report on a little-known alternative – an epigenetic therapy that fights plaque-hardened arteries in a novel manner. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE